These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 33903122

  • 21. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 22. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J.
    Theranostics; 2021 Jun; 11(12):6006-6018. PubMed ID: 33897895
    [Abstract] [Full Text] [Related]

  • 23. HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma.
    Lin X, Zuo S, Luo R, Li Y, Yu G, Zou Y, Zhou Y, Liu Z, Liu Y, Hu Y, Xie Y, Fang W, Liu Z.
    Theranostics; 2019 Jun; 9(25):7583-7598. PubMed ID: 31695788
    [Abstract] [Full Text] [Related]

  • 24. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
    Wang R, Sun Q, Wang P, Liu M, Xiong S, Luo J, Huang H, Du Q, Geller DA, Cheng B.
    Oncotarget; 2016 Feb 02; 7(5):5754-68. PubMed ID: 26735577
    [Abstract] [Full Text] [Related]

  • 25. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z, Ye X, Ma X, Hu X, Yang W, Shi J, Chen G, Gong L.
    Cancer Med; 2020 Jun 02; 9(12):4324-4338. PubMed ID: 32324343
    [Abstract] [Full Text] [Related]

  • 26. DDX5 deficiency drives non-canonical NF-κB activation and NRF2 expression, influencing sorafenib response and hepatocellular carcinoma progression.
    Li Z, Kim W, Utturkar S, Yan B, Lanman NA, Elzey BD, Kazemian M, Yeo Y, Andrisani O.
    Cell Death Dis; 2024 Aug 09; 15(8):583. PubMed ID: 39122708
    [Abstract] [Full Text] [Related]

  • 27. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
    Xia W, Lo CM, Poon RYC, Cheung TT, Chan ACY, Chen L, Yang S, Tsao GSW, Wang XQ.
    Oncotarget; 2017 Jun 13; 8(24):38811-38824. PubMed ID: 28415588
    [Abstract] [Full Text] [Related]

  • 28. Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC.
    Mo C, You W, Rao Y, Lin Z, Wang S, He T, Shen H, Li X, Zhang R, Li B.
    Cell Mol Life Sci; 2024 Jul 05; 81(1):284. PubMed ID: 38967794
    [Abstract] [Full Text] [Related]

  • 29. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Liu Y, Ye X, Zhang JB, Ouyang H, Shen Z, Wu Y, Wang W, Wu J, Tao S, Yang X, Qiao K, Zhang J, Liu J, Fu Q, Xie Y.
    Oncogene; 2015 Oct 29; 34(44):5524-35. PubMed ID: 25684142
    [Abstract] [Full Text] [Related]

  • 30. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
    Cheng BY, Lau EY, Leung HW, Leung CO, Ho NP, Gurung S, Cheng LK, Lin CH, Lo RC, Ma S, Ng IO, Lee TK.
    Cancer Res; 2018 May 01; 78(9):2332-2342. PubMed ID: 29483095
    [Abstract] [Full Text] [Related]

  • 31. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.
    Zhao W, Ma B, Tian Z, Han H, Tang J, Dong B, An G, Cao B, Wang B.
    Br J Cancer; 2021 Mar 01; 124(7):1237-1248. PubMed ID: 33473171
    [Abstract] [Full Text] [Related]

  • 32. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhang QY, Ding W, Mo JS, Ou-Yang SM, Lin ZY, Peng KR, Liu GP, Lu JJ, Yue PB, Lei JP, Wang YD, Zhang XL.
    Acta Pharmacol Sin; 2024 Aug 01; 45(8):1701-1714. PubMed ID: 38609562
    [Abstract] [Full Text] [Related]

  • 33. COLEC10 inhibits the stemness of hepatocellular carcinoma by suppressing the activity of β-catenin signaling.
    Cai MN, Chen DM, Chen XR, Gu YR, Liao CH, Xiao LX, Wang JL, Lin BL, Huang YH, Lian YF.
    Cell Oncol (Dordr); 2024 Oct 01; 47(5):1897-1910. PubMed ID: 39080215
    [Abstract] [Full Text] [Related]

  • 34. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I.
    Mol Oncol; 2019 May 01; 13(5):1311-1331. PubMed ID: 30959553
    [Abstract] [Full Text] [Related]

  • 35. RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.
    Li Z, Caron de Fromentel C, Kim W, Wang WH, Sun J, Yan B, Utturkar S, Lanman NA, Elzey BD, Yeo Y, Zhang H, Kazemian M, Levrero M, Andrisani O.
    Cell Death Dis; 2023 Nov 30; 14(11):786. PubMed ID: 38036507
    [Abstract] [Full Text] [Related]

  • 36. Zinc finger protein X-linked promotes expansion of EpCAM+ cancer stem-like cells in hepatocellular carcinoma.
    Wang C, Fu SY, Wang MD, Yu WB, Cui QS, Wang HR, Huang H, Dong W, Zhang WW, Li PP, Lin C, Pan ZY, Yang Y, Wu MC, Zhou WP.
    Mol Oncol; 2017 May 30; 11(5):455-469. PubMed ID: 28156061
    [Abstract] [Full Text] [Related]

  • 37. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for HCC.
    Chen P, Dong Z, Zhu W, Chen J, Zhou Y, Ye Q, Liao X, Tan Y, Li C, Wang Y, Pang H, Wen C, Jiang Y, Li X, Li B, Aimaier A, Lin L, Sun J, Hou J, Tang L, Hou J, Li Y.
    Hepatology; 2024 Aug 01; 80(2):330-345. PubMed ID: 37820061
    [Abstract] [Full Text] [Related]

  • 38. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B, Cao Y, Meng G, Qian L, Xu T, Yan C, Luo O, Wang S, Wei J, Ding Y, Yu D.
    EBioMedicine; 2019 Jan 01; 39():239-254. PubMed ID: 30555042
    [Abstract] [Full Text] [Related]

  • 39. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH.
    J Exp Clin Cancer Res; 2019 Nov 26; 38(1):474. PubMed ID: 31771617
    [Abstract] [Full Text] [Related]

  • 40. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT, Mou J, Pan YJ, Huo FC, Du WQ, Liang J, Wang Y, Zhang LS, Pei DS.
    J Biomed Sci; 2021 Aug 02; 28(1):56. PubMed ID: 34340705
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.